This formulation should also work. Itraconazole is a low water solubility. They use Poloxamer 407 as a stabilizer and glycerin as a wetting agent. And has low bioavailability. Modified into standard dosage forms such as capsules and tablets for oral use. Jain and his colleagues designed the ciprofloxacin mucoadhesive suspension with an average particle size of 500-1844 nm, showing the preparation steps of the suspension. Atovaquone treats HIV patients with opportunistic Pneumocystis carinii infections complicated by non-infectious Plasmodium falciparum malaria and Leishmania infections. Atovaquone nanosuspension was prepared by Schöler and his colleagues in 2001. This suspension has a good cure for a new mouse model of regenerating Toxoplasma gondii.
It is conceived to prepare an itraconazole suspension with an average particle diameter of 294 nm by using a pearl mill technology using zirconia beads as the grinding medium. The in vitro dissolution profile of the suspension showed that it released 90% within 10 minutes, while the pure and commercially available formulations released 10% and 17% respectively in the same time.
They prepared four different formulations, using different polymers including soy lecithin, pluronic F68, polyvinyl alcohol and polyvinylpyrrolidone. Containing soy lecithin has a faster dissolution rate than others. These suspensions have a release rate of 45-56% within 10 hours, which is much higher than that of conventional ciprofloxacin preparations.
Sigfridsson and his colleagues studied the reduction of particle size and the enhancement of the dissolution of acidic or basic compounds that are difficult to dissolve in water. They showed that there is a correlation between the exposure of acidic compounds in the body and the particle size. Due to improved dissolution and oral bioavailability, suspensions of acidic compounds provide higher exposure in the body. Their research results also show that for a basic compound, at the same dose, due to the high solubility and basic pKa under the pH of the gastric juice, the microsuspension is sufficient, and there is no need to reduce more particle size.
Olmesartan medoxomil is an antihypertensive. Due to its poor water solubility <7.75 μg/ml, its bioavailability is only 26%, and its oral application is limited.